Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Insulet Corporation

PODDNASDAQ
Healthcare
Medical - Devices
$249.10
$0.00(0.00%)
U.S. Market is Open • 15:53

Insulet Corporation Fundamental Analysis

Insulet Corporation (PODD) shows moderate financial fundamentals with a PE ratio of 68.65, profit margin of 9.12%, and ROE of 17.36%. The company generates $2.7B in annual revenue with strong year-over-year growth of 30.73%.

Key Strengths

Current Ratio2.78

Areas of Concern

Cash Position4.21%
PEG Ratio240.27
We analyze PODD's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 75.3/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B
75.3/100

We analyze PODD's fundamental strength across five key dimensions:

Efficiency Score

Weak

PODD struggles to generate sufficient returns from assets.

ROA > 10%
7.75%

Valuation Score

Weak

PODD trades at a premium to fair value.

PE < 25
68.65
PEG Ratio < 2
240.27

Growth Score

Moderate

PODD shows steady but slowing expansion.

Revenue Growth > 5%
30.73%
EPS Growth > 10%
-41.21%

Financial Health Score

Excellent

PODD maintains a strong and stable balance sheet.

Debt/Equity < 1
0.69
Current Ratio > 1
2.78

Profitability Score

Moderate

PODD maintains healthy but balanced margins.

ROE > 15%
17.36%
Net Margin ≥ 15%
9.12%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is PODD Expensive or Cheap?

P/E Ratio

PODD trades at 68.65 times earnings. This suggests a premium valuation.

68.65

PEG Ratio

When adjusting for growth, PODD's PEG of 240.27 indicates potential overvaluation.

240.27

Price to Book

The market values Insulet Corporation at 11.20 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

11.20

EV/EBITDA

Enterprise value stands at 34.16 times EBITDA. This signals the market has high growth expectations.

34.16

How Well Does PODD Make Money?

Net Profit Margin

For every $100 in sales, Insulet Corporation keeps $9.12 as profit after all expenses.

9.12%

Operating Margin

Core operations generate 17.50 in profit for every $100 in revenue, before interest and taxes.

17.50%

ROE

Management delivers $17.36 in profit for every $100 of shareholder equity.

17.36%

ROA

Insulet Corporation generates $7.75 in profit for every $100 in assets, demonstrating efficient asset deployment.

7.75%

Following the Money - Real Cash Generation

Operating Cash Flow

Insulet Corporation produces operating cash flow of $569.16M, showing steady but balanced cash generation.

$569.16M

Free Cash Flow

Insulet Corporation generates strong free cash flow of $377.61M, providing ample flexibility for dividends, buybacks, or growth.

$377.61M

FCF Per Share

Each share generates $5.37 in free cash annually.

$5.37

FCF Yield

PODD converts 2.22% of its market value into free cash.

2.22%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

68.65

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

240.27

vs 25 benchmark

P/B Ratio

Price to book value ratio

11.20

vs 25 benchmark

P/S Ratio

Price to sales ratio

6.26

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.69

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.78

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.17

vs 25 benchmark

ROA

Return on assets percentage

0.08

vs 25 benchmark

ROCE

Return on capital employed

0.19

vs 25 benchmark

How PODD Stacks Against Its Sector Peers

MetricPODD ValueSector AveragePerformance
P/E Ratio68.6529.43 Worse (Expensive)
ROE17.36%800.00% Weak
Net Margin9.12%-20145.00% (disorted) Weak
Debt/Equity0.690.30 Weak (High Leverage)
Current Ratio2.784.64 Strong Liquidity
ROA7.75%-17936.00% (disorted) Weak

PODD outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Insulet Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

175.54%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

3243.88%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

-100.00%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ